Fluncab PR Tablet SR is a combination medication containing Propranolol 40mg and Flunarizine 10mg, formulated to provide sustained relief in the management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, works by reducing heart rate, blood pressure, and myocardial oxygen demand, making it effective in preventing migraine attacks and controlling hypertension. Flunarizine, a calcium channel blocker with antihistaminic properties, helps prevent migraine by inhibiting calcium influx into vascular smooth muscle cells, thereby stabilizing vascular tone and reducing neuronal excitability. The sustained-release formulation ensures a gradual and prolonged release of active ingredients, enhancing patient compliance by reducing dosing frequency and maintaining steady plasma levels. Fluncab PR is typically prescribed for patients experiencing frequent migraine episodes, especially those with concomitant cardiovascular risk factors, and may also be beneficial in managing vertigo and certain types of epilepsy. Common side effects may include fatigue, dizziness, gastrointestinal discomfort, and mild hypotension. It is contraindicated in patients with asthma, bradycardia, or severe hepatic impairment. Patients should consult their healthcare provider before use, particularly if pregnant, breastfeeding, or taking other medications, to avoid potential drug interactions and adverse effects.